Moleculin Biotech Inc. (MBRX)
NASDAQ: MBRX
· Real-Time Price · USD
1.03
0.02 (1.98%)
At close: May 02, 2025, 3:59 PM
1.06
2.42%
After-hours: May 02, 2025, 05:53 PM EDT
1.98% (1D)
| Bid | 1.02 |
| Market Cap | 14.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.76M |
| EPS (ttm) | -6.32 |
| PE Ratio (ttm) | -0.16 |
| Forward PE | -0.64 |
| Analyst | Buy |
| Ask | 1.06 |
| Volume | 218,419 |
| Avg. Volume (20D) | 5,702,879 |
| Open | 1.04 |
| Previous Close | 1.01 |
| Day's Range | 1.00 - 1.05 |
| 52-Week Range | 0.40 - 5.44 |
| Beta | 2.20 |
About MBRX
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 17
Stock Exchange NASDAQ
Ticker Symbol MBRX
Website https://www.moleculin.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 479.71% from the latest price.
Stock Forecasts2 months ago
+202.38%
Moleculin Biotech shares are trading higher after ...
Unlock content with
Pro Subscription
4 months ago
+14.72%
Moleculin Biotech shares are trading higher after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model which demonstrated significant activity.
